Articles On IDT Australia (ASX:IDT)

The ASX200 closed down 0.75% at 8,193 points. Analyst consensus is now that Trump will introduce the tariffs he’s forewarned, and local markets have priced it in. Aussie 3Y government bond yields suggest the RBA now won’t cut until Se...

IDT Australia (ASX:IDT) has confirmed its proposed takeover offer from a company called Myndbio for 15cps has been scrapped. While that deal was higher than IDT’s 11.5cps closing price on Tuesday, IDT says that somewhere along the way d...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Neuren shows promise in Angelman drug but shares down 7pc Avita aims for profitability by Q3 FY25 IDT lands $2.5-$4m mRNA contract with Sanofi   Neuren’s Angelman drug shows promise Market darling Neuren Pharmaceuticals (ASX:NEU) has just...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

HITIQ has secured a pivotal US patent for its Nexus technology BlinkLab has joined forces with Mental Care Group in Europe to enhance ADHD diagnosis IDT Australia has reported a strong finish to the fiscal year   HITIQ gets US patent HITI...

Pharmaceutical manufacturer and medicinal cannabis group IDT Australia (ASX: IDT) has sweetened the pot for potential international suitor Myndbio after reporting a 92 per cent lift in revenue for FY24. IDT, which revealed last month it re...

The cannabis industry is poised for growth, driven by evolving legalisation globally Investment opportunities therefore exist across the sector We take a look at the ASX weed stock winners over the past month    The cannabis industry is c...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

FDA panel rejects MDMA for PTSD treatment, citing safety and data concerns Advocates argue MDMA’s benefits outweigh risks, call for further research. South Africa legalises personal cannabis use, setting precedent for African nations    G...

Aussie shares rally Rate sensitive stocks gain, led by Tech FTL soars on Newfoundland deal   Aussie shares climbed strongly on Thursday closing above 7,820 as major global central banks began to cut interest rates and in the US, the S&amp...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Pharmaceutical manufacturing company IDT Australia (ASX: IDT) has been awarded a grant by the Victoria state government to partly fund the establishment of Australia’s first current good manufacturing practice antibody-drug-conjugate (ADC)...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

Australian shares declined sharply following stronger-than-expected US retail sales data, dampening hopes for interest rate cuts and triggering a 1.26 per cent drop to the S&P/ASX 200, marking the third consecutive session of losses. Th...

  Paul McDonald – CEO – IDT Australia (ASX:IDT) is an expert partner in the production and manufacture of pharmaceutical products, including medicinal cannabis.

Study shows cannabis can kill melanoma cells Germany has voted to legalise cannabis possession The best performing ASX weed stocks over the past month   It hasn’t been a stellar month for global cannabis stocks, with the index falling by...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

By Tim Boreham, Editor, The New Criterion Profit season brings out the best and worst in small caps – and sometimes both at once While inconsistent, the just-concluded profit reporting season has provided succour to investors in the small-c...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Mike Tyson has spoken out against the jailing of cannabis users Iron Mike owns his own cannabis brand called TYSON 2.0 We take a look at the best performing ASX weed stocks over the past month    There are currently at least 3,000 individ...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Jamaican nettletree is said to contain traces of cannabidiol (CBD) Victoria set to launch a medical cannabis driving trial for patients  How ASX weed stocks have performed over the past week and month   Scientists in Brazil said they’ve d...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

IDT provides strong quarterly update Paradigm tumbles 30pc after emerging from trading halt   IDT’s growth driven by all business segments Victoria-based pharmaceutical manufacturing company, IDT Australia (ASX:IDT), provided an update on...

Cannabis stocks could rise after the removal of US House Speaker Montu says TGA has to allow the term ‘medicinal cannabis’ to be used We look at the best performing ASX weed stocks over the past month   Some experts believe cannabis stock...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Big win for cannabis as SAFER Banking Act set to be passed in the US Australia’s cannabis industry remains robust this year, says TGA We look at how ASX weed stocks have performed over the past weeks   A huge win for cannabis as US SAFER...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Cannabis stocks jumped after marijuana rescheduling recommendation in the US Study in Australia shows cannabis is effective on a range of conditions We take a look at the best performing ASX stocks over the past week   Cannabis stocks ope...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

The US is about to follow Australia’s footsteps and approve psychedelics The FDA is currently awaiting a pivotal survey conducted by MAPS And here’s how the ASX weed stocks have performed over the past week   In July of this year, Austral...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Tim Boreham outlines the rise and fall of IDT Australia, and its potential revival in the cannabis and psychedelic drug market. by Tim Boreham ASX Code: ((IDT)) Share price: 6.7 cents Shares on issue: 351,337,149 Market cap: $23.5m Chief ex...

Mastercard says no to weed transactions New York is where weed is happening Jeremy Buckingham pulls a stunt at NSW Parliament   Here’s a quick snapshot of cannabis news making headlines over the past week: Mastercard has told banks to sto...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Social media platforms are rushing to update their advertising policies on cannabis Meta was the most recent platform to do so Australia’s TGA is clamping down on CBD advertising in Australia   With regulations on cannabis use moving fast...

Since TGA’s down-scheduling of CBD last year, no products have been sold in Australia But the race to market has been seemingly won by Bod Science following a ‘landmark update’ Stockhead reached out to BOD’s CEO, Jo Patterson   Amidst gro...

The ASX is expected to open lower today, following a downward trend on global markets overnight. Investors are said to be eagerly awaiting testimony from US Federal Reserve Chair Jerome Powell tomorrow. On home soil, here are some ASX...

The weed industry has slumped as it faces several headwinds But new data suggests the industry will grow significantly over the next decade We take a look at how the ASX weed stocks have performed over the past week   As we head into the...

S&P/ASX 200 closes up 1% – its best performance in about a week  All sectors bar IT and Utilities had green days, with Discretionary and Utilities outperforming Resources & Energy Group had a +183% stonker of a day on its you-beaut...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...